Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06), Zacks reports. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $5.70 on Monday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.29 billion, a PE ratio of -3.73 and a beta of 1.00. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The stock has a fifty day moving average price of $5.82 and a 200-day moving average price of $6.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Recursion Pharmaceuticals stock. Brighton Jones LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,261 shares of the company's stock after acquiring an additional 6,699 shares during the quarter. Brighton Jones LLC's holdings in Recursion Pharmaceuticals were worth $137,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.